Metabolic PET/CT Imaging in Thyroid Cancer

2018 ◽  
pp. 61-66
Author(s):  
Ioan Prata
Keyword(s):  
2020 ◽  
Vol 34 (9) ◽  
pp. 663-674
Author(s):  
Murat Tuncel ◽  
Saadettin Kılıçkap ◽  
Nilda Süslü

2019 ◽  
Vol 12 (4) ◽  
pp. e227910
Author(s):  
Kanhaiyalal Agrawal ◽  
P Sai Sradha Patro ◽  
C Preetam

There is literature evidence showing utility of somatostatin receptor (SSTR) positron emission tomography-CT (PET-CT) imaging in differentiated thyroid cancer with Thyroglobulin Elevated and Negative Iodine Scan (TENIS). These patients are less benefited with I-131 therapy and surgery remains only curable option if disease could be localised. If surgery is not feasible, other therapeutic options are not promising. However, if these patients show strongly positive SSTR imaging, then possibility of peptide receptor radionuclide therapy may be explored. As SSTR PET-CT imaging is expensive and not widely available, Technetium-99m (Tc-99m) hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC), which is a Single photon emission computed tomography (SPECT) tracer, can be used. We are documenting a case of raised serum thyroglobulin antibody and negative I-131 whole body scan with disease recurrence localised on Tc-99m HYNIC-TOC scan.


2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e17555-e17555 ◽  
Author(s):  
Poorni Manohar ◽  
David Brandel ◽  
Emily Light Bellile ◽  
Francis P. Worden ◽  
Anca M Avram

2011 ◽  
Vol 36 (12) ◽  
pp. e180-e185 ◽  
Author(s):  
Camila Mosci ◽  
Andrei Iagaru
Keyword(s):  

2020 ◽  
Vol 52 (03) ◽  
pp. 158-167 ◽  
Author(s):  
Gundula Rendl ◽  
Lukas Rettenbacher ◽  
Gregor Schweighofer-Zwink ◽  
Lukas Hehenwarter ◽  
Christian Pirich

AbstractThe aim of the study was to evaluate the clinical impact of pre-ablation rhTSH-stimulated fluorine-18 fluorodeoxyglucose (F-18 FDG) PET/CT in addition to post-therapeutic whole body radioiodine scanning in patients with intermediate to high risk differentiated thyroid carcinoma (DTC). This was a retrospective single center study including 73 patients with thyroid cancer (44 females, mean age 43.2±16.2 years, 62% papillary, 31% follicular, 7% poorly differentiated). All patients underwent ablative radioiodine treatment (mean activity: 3661±673 MBq I-131) using rhTSH after thyroidectomy and lymph node (LN) dissection (01/2013–10/2016) and TSH-stimulated F-18 FDG PET/CT (4 MBq/kg body weight, low dose CT). Post-treatment I-131 whole body scan (I-131 WBS) was obtained 9 days afterwards in planar technique and in case of equivocal or abnormal findings using SPECT/CT. Thirty-one patients (42%) showed F-18 FDG avid lesions, 14 patients showed more FDG than iodine positive lesions and 5 patients more iodine positive lesions in I-131 WBS, respectively. Fifty-three patients showed identical F-18 FDG PET/CT and I-131 WBS. The initial treatment plan was changed from follow-up to therapy (surgery, systemic therapy using tyrosine-kinase inhibition) in 11 patients (15%) on the basis of F-18 FDG PET/CT imaging. Six of these 11 patients had papillary thyroid cancer. Three patients with histologically proven LN metastases had stimulated thyroglobulin-levels<2.0 ng/ml. Our study demonstrated a clinical benefit of pre-ablation rhTSH-stimulated F-18 FDG PET/CT imaging in about 20% of patients with intermediate to high risk DTC, leading to change in patient management in 15%.


2013 ◽  
Author(s):  
Maria Kallergi ◽  
Dimitrios Menychtas ◽  
Alexandros Georgakopoulos ◽  
Nikoletta Pianou ◽  
Marinos Metaxas ◽  
...  

2006 ◽  
Vol 60 (8) ◽  
pp. 494
Author(s):  
Cristina Nanni ◽  
Domenico Rubello ◽  
Stefano Fanti ◽  
Mohsen Farsad ◽  
Valentina Ambrosini ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Pet Ct ◽  

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Qiuyu Lin ◽  
Qianle Qi ◽  
Sen Hou ◽  
Zhen Chen ◽  
Nan Jiang ◽  
...  

This article explores the value of wall F-FDG PET/Cr imaging in the diagnosis of thyroid cancer, studies its ability to distinguish benign and malignant thyroid lesions, and seeks ways to improve the accuracy of diagnosis. The normal control group selected 40 patients who came to our center for physical examination. In the normal control group, the average value of the standard uptake value of both sides of the thyroid was used as the SUV of the thyroid gland and the highest SUV value of the patient's lesion (SUV max) represented the SUV of the lesion. After injection of imaging agent 18F-FD1G, routine imaging was performed at 1h, time-lapse imaging was performed at 2.5 h, and the changes with conventional imaging were compared to infer the benign and malignant lesions. We used SPSS software to carry out statistical analysis, respectively, carrying out analysis of variance, paired t-test, independent sample t-test, and linear correlation analysis. In the thyroid cancer group, 87.5% of the delayed imaging SUV was higher than the conventional imaging SUV, while 83.33% of the benign disease group had a lower SUV than the conventional imaging SUV. 18F-FDG PET/CT imaging has higher sensitivity and specificity for the diagnosis of recurrence or metastasis in patients with Tg positive. However, it has lower sensitivity and specificity for the diagnosis of 131I-Dx-WBS negative DTC and 18F-FDG PET/CT. The specificity increases with the increase of serum Tg level. The above results confirm that 18F-FDG PET/CT imaging is of great significance for the diagnosis of recurrence or metastasis in patients; with PET/CT imaging, the results changed 16.13% of the Tg-positive and 131I-Dx-WBS negative DTC patients' later treatment decision. The decision-making and curative effect evaluation have certain value.


Sign in / Sign up

Export Citation Format

Share Document